文献速递产科母胎医学

Nestorone在炎症诱导早产小鼠模型中抗炎并预防早产

Nestorone, a potent progestin, exhibits anti-inflammatory activity and prevents preterm birth in murine models of premature labor.
PubMed 文献 · Am J Obstet Gynecol · 2026-08-10

本研究比较高效孕激素Nestorone与孕酮在炎症触发早产小鼠模型中的效果。Nestorone在更低剂量(0.02 mg/日 vs 孕酮2 mg/日)下即显著降低早产率,并调控炎症因子表达,支持其用于早产预防的转化研究。

要点

  • Nestorone在系统性炎症模型中使早产率从100%降至8%。
  • Nestorone在宫内炎症模型中使早产率从100%降至0%。
  • Nestorone在更低剂量下展现与孕酮相当的抗炎及保胎效果。

核心结论

  • Nestorone与孕酮均能减少炎症诱导的早产,且Nestorone在显著更低剂量下达到相当疗效。

研究设计与样本

  • 临床前研究:采用转染细胞评估孕激素受体与糖皮质激素受体转录活性,并用人外周血单核细胞、子宫平滑肌细胞和肺上皮细胞系检测炎症调节作用。
  • 体内实验:定时妊娠小鼠于妊娠第15、16天分别给予Nestorone(0.02 mg/只/日)或孕酮(2 mg/只/日),随后经腹腔或宫内注射内毒素诱导早产。

主要发现

  • Nestorone在受试孕激素中孕激素受体介导的转录活性最高,仅有轻度糖皮质激素受体活性。
  • Nestorone可减弱内毒素诱导的TNF-α和IL-6表达,并增加抗炎因子IL-10表达,在匹配浓度下与孕酮效果总体相当。
  • 系统性炎症模型中,早产率从内毒素对照组的100%(n=12/12)降至加用Nestorone或孕酮后的8%(n=1/12),约降低92%。
  • 宫内炎症模型中,早产率从100%(n=11/11)降至Nestorone和孕酮组的0%(n=0/10),降低100%。

临床怎么用

  • Nestorone可能作为高效孕激素用于炎症相关早产预防的进一步转化研究。

局限性

  • 证据来自小鼠模型和体外细胞实验,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preterm birth is the leading cause of neonatal and infant mortality worldwide. Vaginal progesterone reduces the rate of preterm birth by approximately 45% in women with a singleton gestation and a mid-trimester sonographically short cervix, but it is not effective in women with a prior spontaneous preterm birth who do not have cervical shortening. Whether a more potent, next-generation progestin could provide greater protection against preterm birth in high-risk populations has not been established. Experimental models of acute systemic and intrauterine inflammation are well-established and reproducible triggers of early and consequential preterm labor can provide a rigorous biologic context in which to compare progestational efficacy. Nestorone (segesterone acetate) is a highly potent and selective progestin approved by the US Food and Drug Administration for contraceptive use and widely used clinically. OBJECTIVE: To determine whether the highly potent progestin, Nestorone, administered at a substantially lower dose than progesterone can prevent preterm birth in established mouse models of inflammation-triggered parturition and to characterize its progestational and inflammation-modulating properties in preclinical systems. STUDY DESIGN: Nestorone and comparator progestins were evaluated for transcriptional activation of human progesterone and glucocorticoid receptors in transfected cells. Inflammation-modulating effects were examined in endotoxin-stimulated human peripheral blood mononuclear cells, uterine smooth muscle cells, and lung epithelial cell lines using cytokine profiling and quantitative polymerase chain reaction. In vivo efficacy was assessed in timed-pregnant mice treated with Nestorone or progesterone (0.02 mg or 2 mg per mouse per day, respectively) on gestational days 15 and 16, followed by a systemic (intraperitoneal) or a local (intrauterine) endotoxin challenge to induce preterm labor. RESULTS: (1) Nestorone exhibited the highest progesterone receptor-mediated transcriptional activity among the progestins tested, with only mild glucocorticoid receptor activity; (2) Nestorone attenuated endotoxin-induced expression of proinflammatory cytokines, including tumor necrosis factor α and interleukin-6, and increased expression of the anti-inflammatory cytokine interleukin-10 in human immune, uterine and lung cells; these effects were generally comparable to progesterone at matched concentrations; (3) Nestorone, at a substantially lower dose of 0.02 mg/day compared to 2 mg/day dose of progesterone, prevented preterm delivery, in murine models of both systemic and local intrauterine inflammation-induced preterm labor. For example, in a systemic inflammation model, preterm birth decreased from 100% (n=12/12) in endotoxin-treated controls to 8% (n=1/12) with the addition of Nestorone or progesterone (∼92% reduction). In addition, in an intrauterine inflammation model, preterm birth was reduced from 100% (n=11/11) to 0% for both Nestorone and progesterone (n=0/10; 100% reduction). CONCLUSION: In established models of early and consequential preterm labor, Nestorone and progesterone both reduced preterm birth, with Nestorone achieving comparable efficacy at a substantially lower dose. These findings support the concept that the enhanced progestational potency of Nestorone may be beneficial in maintaining pregnancy under biologic stress conditions, justifying further translational investigation of Nestorone for preterm birth prevention.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kumar N, Singer P, Sachdeva R, et al. Nestorone, a potent progestin, exhibits anti-inflammatory activity and prevents preterm birth in murine models of premature labor. Am J Obstet Gynecol. 2026. PMID: 42575275. doi:10.1016/j.ajog.2026.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。